Health News

Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.

Read more

Filed under: Pharmacy News
Tags: leukemia, Pharmacy

Related posts

• YM BioSciences reports preclinical results of CYT387 in multiple myeloma (0)
  YM BioSciences Inc., today reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the advance online edition of Leukemia on July 26, 2011. Read more [tags] Pharmacy News [/tags]
  
  
• Wake Forest Baptist Medical Center And Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial Of CPI-613 In Acute Myeloid Leukemia (0)
  Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia (AML)... Read more [tags] Pharmacy News [/tags]
  
  
• Vorinostat in addition to chemotherapy drugs improves remission rates in AML patients (0)
  Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center reported at the 53rd Annual Meeting of the American Society of Hematology. Read more [tags] Pharmacy News [/tags]
  
  
• Vion Pharmaceuticals To Present Data On Onrigin(TM)at The ASCO(R) Annual Meeting (0)
  VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced that an analysis of clinical data of its lead anticancer agent Onrigin (laromustine) Injection in acute myeloid leukemia (AML) would be presented in a poster at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. Read more [tags] Pharmacy News [/tags]
  
  
• Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial (0)
  VION PHARMACEUTICALS, INC. announced today that it had filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin™ (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML). The primary [...]